RxDoctor Payments Data

Don Tran, MD

Family Medicine · Bakersfield, CANPI 1215079389

Payments from drug & device makers

$688in general payments, 2019–2025

Across 30 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$247
  • Johnson & Johnson$92
  • Angiodynamics, Inc.$64
  • Lilly USA, LLC$62
  • Kiniksa Pharmaceuticals International, PLC$37
  • Sanofi-aventis U.S. LLC$32
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$688 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$6,509
Medicare patients
31
Services billed
77

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide203$219,299
JardianceEmpagliflozin60$64,265
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog44$50,847
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog73$49,384
TradjentaLinagliptin42$36,314
XareltoRivaroxaban41$35,333
FarxigaDapagliflozin Propanediol37$34,931
EliquisApixaban32$23,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog93$23,101
TrulicityDulaglutide16$21,228
JanuviaSitagliptin Phosphate20$20,273
InvokanaCanagliflozin20$19,186
EntrestoSacubitril/Valsartan27$18,865
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog41$16,927
Tresiba Flextouch U-200Insulin Degludec13$13,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$219,299203 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$17$106,564114 claims
Johnson & JohnsonXarelto, Invokana$92$54,52061 claims
AstraZenecaFarxiga$247$34,93137 claims
PfizerEliquis$31$23,95832 claims
Lilly USA, LLCTrulicity$62$21,22816 claims
AbbVieLinzess$32$13,48521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →